The endocrine system intricately regulates male sexual development and health, and disorders in the hypothalamic-pituitary-gonadal axis can lead to hypogonadism, gynecomastia, sexual dysfunction, and infertility.
Key Findings
Background
Testosterone replacement therapy can be considered for symptomatic hypogonadism but carries significant risks.
Risks include azoospermia and polycythemia.
The impact on cardiovascular disease remains uncertain.
Testosterone replacement therapy is indicated for symptomatic hypogonadism rather than asymptomatic low testosterone.
Background
Gynecomastia results from a high estrogen-to-androgen ratio.
The condition arises mostly from either excess estrogen or decreased androgens.
Gynecomastia is a disorder of the hypothalamic-pituitary-gonadal axis.
The underlying mechanism involves an imbalance between estrogenic and androgenic hormonal activity.
Background
Sexual dysfunction in males is more commonly secondary to psychological or metabolic disorders rather than endocrine causes.
Endocrine etiologies including hypogonadism should be ruled out when indicated.
A workup for endocrine causes is recommended as part of the evaluation of sexual dysfunction.
Sexual dysfunction is listed among the disorders that can result from disruption of the hypothalamic-pituitary-gonadal axis.
Background
The hypothalamic-pituitary-gonadal axis plays a central role in regulating male sexual development and health.
The endocrine system influences masculinization, sexual libido, muscle mass, bone density, and overall vitality.
Disorders in the hypothalamic-pituitary-gonadal axis can lead to hypogonadism, gynecomastia, sexual dysfunction, and infertility.
The paper addresses these conditions in the context of primary care.